UK ADHD Medication Review & Evidence Planner

Medication Response & Vitals

Record your 12-month timeline, somatic symptoms, and transition goals.

Current Prescribed Treatment

Desired Transition Target

Review Interval (Months)

Efficacy (1-5)

2/5

Weight Loss (kg)

Body Weight Loss (%)

Appetite Status

12-Month Weight & Tolerance Trajectory Clinically Significant (>10% Loss)

NICE Clinical Review Checklist (NG87)

Medical History & Baseline Checked Blood pressure, resting pulse, and baseline records validated.

Documented Unintended Weight Loss >10% Meets NICE caution criteria for adverse gastrointestinal impact.

Substance History: Past Self-Medication vs. Current Stability Pre-titration cannabis cessation addressed; constructive risk appraisal.

ADHD Executive Dysfunction Rebound Noted Diminishing focus/organization despite consistent daily dosing.

Core Consultation Talking Points (one per line)

Structured Review Agenda & Brief

Real-time consultation plan aligned with UK RTC and NICE NG87 guidelines.

Reported Efficacy 2 / 5 (Suboptimal)

Weight Loss (12 Mo) -8.0 kg (-10.5%)

Prioritized Clinical Agenda

NICE NG87 Guideline Transition Justification

First-line Treatment Review: Atomoxetine is valid for non-responders or intolerance, but NICE recommends reassessing if therapeutic response wanes after initial 6–12 months.
Adverse Weight/Appetite Impact: A documented 10.5% weight loss satisfies clinical threshold for treatment modification or specialist nutrition/pharmacotherapy review.
Constructive Substance Dialogue: Historical recreational cannabis ceased pre-titration; NICE guidelines emphasize collaborative risk management rather than blanket denial of first-line stimulant care.

Requested Clinician Outcome

Agreement to titrate onto Stimulant medication (e.g., Methylphenidate / Lisdexamfetamine) under RTC specialist supervision, including baseline cardiovascular metrics and appetite monitoring.

Clinical References & Guidance:

NICE Guideline NG87: Attention deficit hyperactivity disorder: diagnosis and management (Updated UK Guidance). NHS Right to Choose (RTC) provider review framework (Harrow Health / Clinical Partners / Psychiatry UK protocols). This tool generates a personal preparation outline for annual ADHD consultations; always discuss clinical adjustments directly with your NHS or RTC psychiatrist.

Reading the preparation brief and its illustration

Your browser does not support video.

Read the explanation

The preparation page stores weight change in kilograms and percentage as two separate inputs. Changing one does not calculate the other. Its saved eight kilograms and ten point five percent therefore are scenario entries rather than independently checked clinical measurements. The two illustrative bars compare eight and ten point five numeric input units at twenty five pixels per unit, not medically comparable quantities. This video explains the form implementation only. It does not validate medication effects, recommend a treatment change, confirm guidelines or determine the importance of any symptom. The chart endpoint vertical coordinate is the smaller of eighty and twenty five plus four point five times entered percentage. At ten point five percent it reaches seventy two point two five SVG units. At twenty percent it saturates at eighty. The bars scale both coordinates by four. The kilogram field changes the endpoint label, while the curve geometry uses percentage. Middle chart points are fixed and its labels stay month three, month six and month twelve. This is an authored illustration, not a reconstruction of recorded weight over time or a medical monitoring tool. The efficacy slider can change from two out of five to five out of five, updating the page label to optimal. The exported brief still appends the fixed word Suboptimal to the numeric rating. The bars compare two and five at sixty pixels per rating point. The review duration field also does not replace every fixed twelve month statement in the generated template. Users should inspect the actual exported text against their entered notes and accurate records. This implementation explanation makes no recommendation about medication, titration or clinical eligibility, and does not verify the template medical statements.